Program
vadadustat
Also written as “Vadadustat”, “AKB-6548” and “MT-6548”.
Its studies are mostly in Anemia · Renal Insufficiency, Chronic, led by 2 companies.
Drug pageVadadustat: every studyAll 40 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akebia Therapeuticsits history only | 320 open or running | phase 3since Jan 4, 2016 | Nov 5, 2010 | none ahead |
| Tanabe Pharma | 40 open or running | phase 3since Oct 30, 2017 | Oct 30, 2017 | none ahead |
Also a collaborator on its studies: Otsuka.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Tanabe Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2015Named vadadustatINNProposed as its International Nonproprietary Name in WHO's List 114 · before, AKB-6548, MT-6548
- Oct 30, 2017First study: phase 3 study in AnemiaFirst studyNCT03329196 · 304 enrolled · Japan
- Dec 27, 2017Phase 3 study in AnemiaNCT03402386 · 42 enrolled · Japan
- Feb 14, 2018Phase 3 study in AnemiaNCT03439137 · 323 enrolled · Japan
- Mar 5, 2018Phase 3 study in AnemiaNCT03461146 · 24 enrolled · Japan
TargetBeta
“Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| roxadustatrule | Astellas Pharma | phase 4 | 47 |
| daprodustatrule | GlaxoSmithKline | phase 3 | 33 |
Studies
All 4 Tanabe Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03461146Anemia · Japan | 3 | Completed | Dec 3, 2018 | 24 |
| NCT03439137Anemia · Japan | 3 | Completed | Dec 12, 2018 | 323 |
| NCT03402386Anemia · Japan | 3 | Completed | Nov 22, 2018 | 42 |
| NCT03329196Anemia · Japan | 3 | Completed | Jan 8, 2019 | 304 |
How it is read
Names in the registry
- “Vadadustat”, 19 entries
- “AKB-6548”, 8 entries
- “MT-6548”, 4 entries
- “vadadustat”, 4 entries
- “vadadustat reference tablets”, 1 entry
Conditions, from the studies’ own filings
- Anemia, 25 studies
- Renal Insufficiency, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.